Incidence of Atrioventricular Block After Valve Replacement in Carcinoid Heart Disease

Igor Sunjic, Doosup Shin, Katlynd M. Sunjic, Jesal V. Popat, Thanh Tran, Sanders H. Chae, Christiano C. Caldeira, Jonathan R. Strosberg, Dany Sayad

Abstract

Background: Carcinoid heart disease (CaHD) is a rare condition that has a high impact on the morbidity and mortality of its patients. Once heart failure symptoms develop in the patient with CaHD, cardiac valve surgery is often the only effective treatment. Although atrioventricular block (AVB) is a known postoperative complication of the valve surgery, the incidence of AVB in this population has not been well described.

Methods: Comprehensive records were collected retrospectively on consecutive patients with CaHD who underwent a valve surgery at a tertiary medical center from January 2001 to December 2015. We excluded patients with pre-existing permanent pacemaker (PPM).

Results: Nineteen consecutive patients were included in this study and 18 of them underwent at least dual valve (tricuspid and pulmonary valve) replacement surgery. Our 30-day post-surgical mortality was 0%. During the 6-month observation period following the surgery, 31.5% (n = 6) required PPM implantation due to complete AVB. There was no statistical difference in baseline characteristics and electrocardiographic and echocardiographic parameters between the patients who did or did not require PPM placement.

Conclusions: Our study revealed that almost one-third of CaHD patients who underwent a valve replacement surgery developed AVB requiring PPM implantation. Due to high incidence of PPM requirement, we believe that prophylactic placement of an epicardial lead during the valve surgery can be helpful in these patients to reduce serious complication from placement of pacemaker lead on a later date through a prosthetic valve.

Keywords: Carcinoid heart disease; Atrioventricular block; Pacemaker; Valve disease; Valve replacement surgery

Introduction

Carcinoid heart disease (CaHD) is a fibrotic valvular process that occurs in patients with longstanding carcinoid syndrome and highly elevated levels of circulating serotonin [1]. Prior to development of effective systemic treatments for reduction of circulating serotonin levels, CaHD was reported to develop in approximately 50% of carcinoid syndrome patients [2]. In CaHD, the right-sided heart valves are primarily affected because of their direct exposure to circulating blood serotonin, leading to right heart failure. Once patients with CaHD develop heart failure symptoms, the only effective treatment option is valve surgery, which has shown to decrease mortality and improve functional symptoms [3-8]. Majority of those patients required both tricuspid valve (TV) and pulmonary valve (PV) surgeries, preferably replacement [7, 9]. In 1995, Connolly and colleagues reported that 30-day mortality in CaHD patients undergoing cardiac surgery was 35% [3]. Subsequent studies have demonstrated a decline in overall operative mortality to 10% or lower after 2000 [7, 10].

A potential complication of the valve surgery for CaHD patients is atrioventricular block (AVB). However, prior studies have not focused on the morbidity associated with this event and the appropriate management of this complication. We therefore sought to examine the incidence of AVB and permanent pacemaker (PPM) implantation following valve replacement in CaHD patients.

Materials and Methods

This retrospective chart review was conducted on consecutive patients with CaHD who were evaluated by a cardiothoracic surgeon for a valve replacement surgery at a tertiary medical...
CaHD was diagnosed with echocardiography and presence of valvular thickening associated with regurgitation or stenosis. Valve surgery was recommended in stable CaHD patients if they had functional symptoms consistent with worsening heart failure or severe valvular dysfunction. Diagnoses of comorbid conditions were determined by the International Statistical Classification of Diseases and Related Health Problems (ICD)-9 or ICD-10 codes, with the exception of coronary artery disease, which had to be confirmed by left heart catheterization. Pre- and post-surgical electrocardiogram (EKG) and transthoracic echocardiogram data were collected and reviewed by an independent cardiologist.

Cardiopulmonary bypass was performed through midline sternotomy. Inflow arterial cannula was placed in the ascending aorta and outflow cannula placed in the superior and inferior vena cava. Operation was performed on a beating heart at normothermia. Bioprosthetic valve was used due to favorable outcomes without need for lifetime anticoagulation [7]. The biggest valve possible on the pulmonic position was used in order to maximize the unload of the weak right ventricle (RV). Our valve of choice was a 29-mm freestyle bioprosthesis. In order to fit the valve, the RV outflow track was consistently enlarged with a patch.

In total, 27 patients were identified with CaHD seeking surgical evaluation for valve replacement during the study period. Among them, seven patients did not undergo surgery due to extensive metastatic disease or comorbid conditions. One patient was excluded due to the presence of a PPM upon initial preoperative evaluation. After these exclusions, 19 patients were finally included in this study.

Table 1 demonstrates characteristics of study participants. The average age was 60.4 ± 1.9 years old and 57.9% were male gender. All 19 patients had symptomatic heart failure (New York Heart Association class III/IV) and were on octreotide therapy prior to the surgery. Two patients had had prior valve replacement and underwent redo valve surgery as a result of worsening disease. Sixteen patients underwent dual valve replacement (TV and PV), two patients underwent triple valve replacement (TV, PV, and aortic valve), and the other one underwent PV replacement.

During the 6-month observation period following surgery, 31.5% (n = 6) required PPM implantation due to complete AVB. There was no statistically significant difference in demographic and comorbidity profile, pre-procedural EKG parameters, and pre- and post-procedural echocardiographic parameters between PPM and non-PPM groups. Also, there was no significant difference in type of surgery between the two groups (P = 0.088). All two patients who underwent triple valve replacement developed AVB and required PPM placement, but number was too small to detect statistical difference. Our 30-day surgical mortality was 0%. Two patients died during the follow-up period, approximately 4 months after the surgery.

Table 2 demonstrates characteristics of patients who developed AVB and required PPM placement following the valve surgery. The mean time to PPM implantation after the surgery was 6.3 ± 0.5 days (median, 6.5 days). Device interrogation done in at least 4 months after the PPM implantation revealed that all patients were still dependent to the PPM except one patient whose interrogation result was not available.

**Discussion**

The majority of CaHD patients develop heart failure symptoms as a result of tricuspid and pulmonary insufficiency leading to right heart chamber dilation. Once they develop heart failure symptoms, the only effective treatment option is a valve surgery, and both TV and PV are usually replaced [7, 10]. In our retrospective study that included 19 patients with CaHD who underwent valve surgery, most patients (n = 18) had at least dual valve replacement (TV and PV), and 30-day operative mortality was 0%. Incidence of complete AVB requiring PPM placement after the surgery was 31.5% during the 6-month follow-up.

The incidence of PPM requirement after TV operation has been known to be higher than that after other valve interventions [11]. During replacement of the TV, independent of valve size, stitches are placed through the TV annulus, which is in close proximity to the AV node. Despite all efforts to avoid surgical injury to the AV node, injury to the node or even edema of the surrounding tissue could cause temporary or permanent AVB. In our study, the incidence of PPM requirement after valve replacement in patients with CaHD was even higher than that after overall TV operations performed in the same hospital during 2014 - 2015 (unpublished data; 24%) or other experienced centers (21-22%) [11, 12]. Although number of cases from our study was not enough to detect statistical significance of such difference, it should be noticed that almost one-third of CaHD patients required PPM placement after the valve replacement. Part of the reason is that those patients required multiple valve replacement, and multivalve surgery is a well-known risk factor for post-operative PPM requirement [13]. In addition, valve replacement is known to be associated with significantly higher risk of post-operative PPM requirement compared with valve repair [13], and all of our patients received valve replacement surgery.

AVB after valve surgery can be transient and recovery of conduction usually occurs before the seventh postoperative day [13, 14]. However, since there are risks of delayed PPM implantation (e.g. prolonged immobilization and hospital
Table 1. Characteristic of Patients With Carcinoid Heart Disease Who Underwent a Valve Replacement Surgery According to Post-Surgical Permanent Pacemaker Placement

| Characteristic                                                                 | Overall (n = 19) | Post-surgical PPM placement |
|--------------------------------------------------------------------------------|------------------|----------------------------|
|                                                                            | PPM (n = 6)      | No PPM (n = 13)            | P value<sup>a</sup> |
| Demographic and comorbidity profile                                         |                  |                            |                     |
| Age<sup>b</sup>, years                                                      | 60.4 ± 1.9       | 63.2 ± 1.9                 | 59.2 ± 2.6          | 0.331 |
| Male                                                                         | 11 (57.9)        | 1 (16.7)                   | 10 (76.9)           | 0.041 |
| Hypertension                                                                 | 12 (63.2)        | 1 (16.7)                   | 11 (84.6)           | 0.010 |
| Diabetes mellitus                                                            | 3 (15.8)         | 1 (16.7)                   | 2 (15.4)            | 1.000 |
| Hyperlipidemia                                                               | 4 (21.1)         | 1 (16.7)                   | 3 (23.1)            | 1.000 |
| Coronary artery disease<sup>c</sup>                                          | 2 (10.5)         | 1 (16.7)                   | 1 (7.7)             | 1.000 |
| Atrial fibrillation                                                          | 7 (36.9)         | 4 (66.7)                   | 3 (23.1)            | 0.129 |
| Obesity<sup>d</sup>                                                          | 4 (21.1)         | 0 (0.0)                    | 4 (33.8)            | 0.255 |
| NYHA class III/IV                                                            | 19 (100)         | 6 (100)                    | 13 (100)            | -     |
| Prior treatment                                                              |                  |                            |                     |
| Prior valve surgery                                                          | 2 (10.5)         | 1 (16.7)                   | 1 (7.7)             | 1.000 |
| Prior octreotide treatment                                                   | 19 (100)         | 6 (100)                    | 13 (100)            | -     |
| Pre-surgical EKG parameters                                                  |                  |                            |                     |
| First degree AVB                                                             | 3 (15.8)         | 0 (0.0)                    | 3 (23.1)            | 0.522 |
| ≥ Second degree AVB                                                          | 0 (0)            | 0 (0)                      | 0 (0)               | -     |
| RBBB                                                                         | 3 (15.8)         | 0 (0.0)                    | 3 (23.1)            | 0.517 |
| Left fascicular block                                                        | 2 (10.5)         | 1 (16.7)                   | 1 (7.7)             | 1.000 |
| PR interval (ms)                                                             | 167.6 ± 13.0     | 158.8 ± 9.8                | 171.6 ± 18.6        | 0.660 |
| QRS interval (ms)                                                            | 102.3 ± 4.0      | 104.2 ± 10.7               | 101.5 ± 3.7         | 0.765 |
| Pre-surgical TTE parameters                                                  |                  |                            |                     |
| LVEF (%)                                                                     | 54.6 ± 1.2       | 56.8 ± 1.9                 | 53.5 ± 1.5          | 0.236 |
| Reduced RV function                                                          | 15 (79.0)        | 4 (66.7)                   | 11 (84.6)           | 0.557 |
| RVSP (mm Hg)                                                                 | 32.0 ± 3.0       | 35.0 ± 9.1                 | 30.9 ± 2.8          | 0.566 |
| Pulmonary insufficiency, moderate to severe                                   | 12 (63.2)        | 2 (33.3)                   | 10 (76.9)           | 0.129 |
| Pulmonary stenosis                                                           | 11 (58.9)        | 3 (50.0)                   | 8 (61.5)            | 1.000 |
| Tricuspid regurgitation, moderate to severe                                   | 18 (94.7)        | 6 (100.0)                  | 12 (92.3)           | 1.000 |
| Tricuspid stenosis                                                           | 6 (31.6)         | 1 (16.7)                   | 5 (38.5)            | 0.605 |
| Post-surgical TTE parameters<sup>a</sup>                                      |                  |                            |                     |
| LVEF (%)                                                                     | 55.6 ± 2.2       | 55.8 ± 4.0                 | 55.5 ± 2.8          | 0.945 |
| Reduced RV function                                                          | 7 (43.8)         | 3 (50.0)                   | 4 (40.0)            | 1.000 |
| RVSP (mm Hg)                                                                 | 30.3 ± 2.5       | 36.0 ± 5.1                 | 28.0 ± 2.7          | 0.161 |
| Type of surgery                                                              |                  |                            |                     |
| PVR                                                                          | 1 (6.3)          | 0 (0.0)                    | 1 (7.7)             | 0.888 |
| PVR + TVR                                                                    | 16 (84.2)        | 4 (66.7)                   | 12 (92.3)           | -     |
| PVR + TVR + AVR                                                              | 2 (10.5)         | 2 (33.3)                   | 0 (0.0)             | -     |
| Post-surgical mortality                                                      | 2 (10.5)         | 1 (16.7)                   | 1 (7.7)             | 1.000 |
| Operative (30 days)                                                          | 0 (0.0)          | 0 (0.0)                    | 0 (0.0)             | -     |
| During 6-months follow up                                                    | 2 (10.5)         | 1 (16.7)                   | 1 (7.7)             | 1.000 |

Values are number (%) or mean ± standard deviation. <sup>a</sup>Fisher’s exact test or t-test. <sup>b</sup>Average age in years at time of surgery or during last visit. <sup>c</sup>Diagnosed via left heart catheterization. <sup>d</sup>Body mass index ≥ 30 kg/m²; AVB: atrioventricular block; AVR: aortic valve replacement; EKG: electrocardiogram; LVEF: left ventricular ejection fraction; ms: millisecond; NYHA: New York Heart Association; PPM: permanent pacemaker; PVR: pulmonary valve replacement; RBBB: right bundle branch block; RV: right ventricle; RVSP: right ventricular systolic pressure; TTE: transthoracic echocardiogram; TVR: tricuspid valve replacement.
The best timing of permanent pacing is still controversial. Per literature review, it is generally recommended to defer the PPM placement no earlier than 5 - 7 days after the surgery [13-15]. In our study, the mean time to PPM implantation after the surgery was 6.3 ± 0.5 days (median, 6.5 days), which was not quite different from what was recommended. Furthermore, device interrogation done in several months after the PPM implantation revealed that those patients continued to be dependent on the PPM.

After TV replacement, placement of an endocardial ventricular pacemaker lead could be difficult. The lead, if placed at a later time through the prosthetic valve, will damage the prosthetic valve with time. It can also increase the risk of prosthetic endocarditis. To prevent such complications, preemptive placement of an epicardial right ventricular pacemaker lead was advised by our team. Therefore, all 19 patients in our study had a bipolar epicardial ventricular lead placed and tunneled underneath the left chest. These leads were well tolerated and relatively easy to connect if PPM needs to be utilized.

This study has several limitations. First, it was a single-center, retrospective study with a small sample size. Secondly, our study period extends over 14 years in which changes in the care of cardiac disease patients in general may have affected the results. Despite above limitations, this is the first study to investigate the incidence of AVB requiring PPM placement after valve replacement surgery in CaHD patients.

Conclusions

In conclusion, our study found that almost one-third of CaHD patients who underwent a valve replacement surgery required post-operative PPM placement due to AVB. Therefore, we believe that prophylactic placement of an epicardial lead during the valve surgery could be helpful in these patients to reduce serious complications that can result from repeat thoracotomy or placement of pacemaker lead on a later date through a prosthetic valve.

Acknowledgments

Parts of this study were presented at American Heart Association Scientific Sessions November 12 - 16, 2016, New Orleans, LA, USA.

Financial Disclosure

None to declare.

Conflict of Interest

All authors have nothing to disclose.

Informed Consent

This study was approved to waive informed consent process by the IRB committee.

Author Contributions

IS and D Sayad contributed to conceptualization; IS, D Shin, KMS, and TT contributed to data curation; IS, D Shin, KMS, and TT contributed to writing and original draft preparation; IS, D Shin, KMS, JVP, SHC, CCC, JRS, and D Sayad contributed to writing, critical review and editing.

References

1. Patel C, Mathur M, Escarcega RO, Bove AA. Carcinoid heart disease: current understanding and future directions. Am Heart J. 2014;167(6):789-795.
2. Pellikka PA, Tajik AJ, Khandheria BK, Seward JB, Callahan JA, Pitot HC, Kvolks LK. Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation. 1993;87(4):1188-1196.
3. Connolly HM, Nishimura RA, Smith HC, Pellikka PA, Mullany CJ, Kvolks LK. Outcome of cardiac surgery for carcinoid heart disease. JAm Coll Cardiol. 1995;25(2):410-416.
4. Moller JE, Pellikka PA, Bernheim AM, Schaff HV, Ru-
bin J, Connolly HM. Prognosis of carcinoid heart disease: analysis of 200 cases over two decades. Circulation. 2005;112(21):3320-3327.
5. Bhattacharyya S, Raja SG, Toumpanakis C, Caplin ME, Dreyfus GD, Davar J. Outcomes, risks and complications of cardiac surgery for carcinoid heart disease. Eur J Cardiothorac Surg. 2011;40(1):168-172.
6. Manoly I, McAnelly SL, Sriskandarajah S, McLaughlin KE. Prognosis of patients with carcinoid heart disease after valvular surgery. Interact Cardiovasc Thorac Surg. 2014;19(2):302-305.
7. Connolly HM, Schaff HV, Abel MD, Rubin J, Askew JW, Li Z, Inda JJ, et al. Early and late outcomes of surgical treatment in carcinoid heart disease. J Am Coll Cardiol. 2015;66(20):2189-2196.
8. Edwards NC, Yuan M, Nolan O, Pawade TA, Oelofse T, Singh H, Mehrzad H, et al. Effect of valvular surgery in carcinoid heart disease: an observational cohort study. J Clin Endocrinol Metab. 2016;101(1):183-190.
9. Warner RRP, Castillo JG. Carcinoid Heart Disease: The Challenge of the Unknown Known. J Am Coll Cardiol. 2015;66(20):2197-2200.
10. Castillo JG, Filsoufi F, Rahmanian PB, Anyanwu A, Zacks JS, Warner RR, Adams DH. Early and late results of valvular surgery for carcinoid heart disease. J Am Coll Cardiol. 2008;51(15):1507-1509.
11. Jokinen JJ, Turpeinen AK, Pitkanen O, Hippelainen MJ, Hartikainen JE. Pacemaker therapy after tricuspid valve operations: implications on mortality, morbidity, and quality of life. Ann Thorac Surg. 2009;87(6):1806-1814.
12. Scully HE, Armstrong CS. Tricuspid valve replacement. Fifteen years of experience with mechanical prostheses and bioprostheses. J Thorac Cardiovasc Surg. 1995;109(6):1035-1041.
13. Koplan BA, Stevenson WG, Epstein LM, Aranki SF, Maisel WH. Development and validation of a simple risk score to predict the need for permanent pacing after cardiac valve surgery. J Am Coll Cardiol. 2003;41(5):795-801.
14. Meimoun P, Zeghdi R, D’Attelis N, Berrebi A, Braunberger E, Deloche A, Fabiani JN, et al. Frequency, predictors, and consequences of atrioventricular block after mitral valve repair. Am J Cardiol. 2002;89(9):1062-1066.
15. Kim MH, Deeb GM, Eagle KA, Bruckman D, Pelosi F, Oral H, Sticherling C, et al. Complete atrioventricular block after valvular heart surgery and the timing of pacemaker implantation. Am J Cardiol. 2001;87(5):649-651, A610.